Category Archives: Uncategorized

Benefits Of Smoke Free Environment

Enactment of smoke-free legislation in Europe and North America,
decreased preterm birth rates and childhood asthma exacerbations by 10%.

To assess the effects of such policies on pregnancy outcomes and risk
for childhood asthma, researchers conducted a meta-analysis of five
North American and six European studies involving >2.5 million
pregnancies and 247,168 asthma exacerbations.

Following the introduction of smoke-free policies, reductions of 10%
were promptly seen in rates of preterm birth and very-small-for-
gestational-age birth. In addition, rates of pediatric asthma
exacerbations fell by 10%.

Been JV et al. Effect of smoke-free legislation on perinatal and child
health: A systematic review and meta-analysis. Lancet 2014 May 3;
383:1549. (http://dx.doi.org/10.1016/S0140-6736(14)60082-9)PubMed
abstract
Kalkhoran S and Glantz SA.Smoke-free policies: Cleaning the air with
money to spare. Lancet 2014 May 3; 383:1526. (http://dx.doi.org/10.1016/S0140-6736(14)60224-5
)PubMed abstract

New treatment for the prevention of HIV in High Risk Individuals

The CDC now recommends daily treatment with Truvada (300 mg tenofovir
disoproxil fumarate and 200 mg emtricitabine) to lower the risk for
HIV acquisition among high-risk adults.

Pre-exposure prophylaxis with Truvada is recommended in the following
groups-

Men who have Sex with Men-
not in a monogamous relationship who engage in unprotected anal
intercourse

Heterosexually active adults who rarely use condoms during sex with
high-risk partners of unknown HIV status

All adults in an ongoing relationship with an HIV-infected partner

Injection drug users who share needles

Individuals must test negative for HIV before beginning Truvada, and
they should be assessed every 3 months thereafter. Those who acquire
HIV should discontinue the drug.

CDC pre-exposure prophylaxis guidelines

Is Too Much Exercise Bad For You?

Two studies in the journal Heart suggest that health benefits may be
curtailed in people who exercise very frequently or very intensely.

In a Swedish study, researchers analyzed data from exercise
questionnaires and hospital records of nearly 45,000 men. Men who
exercised intensively more than 5 hours a week at the age of 30 were
more likely to develop atrial fibrillation (an abnormal heart rythm)
than men who exercised less than 1 hour a week. Their risk was even
higher if they subsequently quit exercising later in life.

In the second study, researchers followed more than 1000 patients with
coronary heart disease. Overall, patients who exercised strenuously 2–
4 days a week had the lowest risk for death and cardiovascular events.
But there was an increase in risk in groups that rarely exercised and
in those who exercised vigorously every day.

Editorialists speculate that intensive exercise may have a
proinflammatory effect that may be especially harmful in some people
with atherosclerotic disease.

CardioExchange.

FDA Approves New Sugar Substitute

The artificial sweetener advantame has been approved for use as an all-
purpose sweetener, making it the sixth sugar substitute to get the nod
from the FDA.

Advantame, which was deemed safe from possible toxic effects in some
35 animal and human studies, does not raise blood sugar levels and
adds few calories to food. Like aspartame, it should be avoided by
people who can’t metabolize phenylalanine, one of the sweetener’s
ingredients.

The product has no brand name yet.

Chronic Medical Conditions Associated with Increased Risk of Shingles.

Researchers have identified several risk factors for shingles that appear to pose a higher risk for younger adults, particularly those under age 50.

Using a U.K. primary care database, researchers identified nearly
150,000 incident cases of zoster over 11 years, matched with roughly
550,000 controls who didn’t have zoster at their index visit.

The following conditions were associated with increased shingles risk:
systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel
disease, chronic obstructive pulmonary disease, asthma, chronic kidney
disease, type 1 diabetes, and depression. These conditions had greater
effects among younger patients. The authors ask “whether targeted
zoster vaccination of specific high risk groups at younger ages is
warranted.”

Patients with contraindications to the vaccine (e.g., lymphoma and
HIV) were at highest risk for zoster, “highlighting the need to
identify strategies to reduce the risk of zoster among these groups,”
they write.

The case-control study appears in BMJ.

Treatment options for Alcohol Dependence

Four medications have clinical value in treating patients with alcohol-
use disorders, according to a review in JAMA.

Researchers examined over 120 studies of medications used for alcohol-
use disorders. Some 23,000 patients were enrolled, most after
detoxification or a period of sobriety.

Acamprosate (a glutamine antagonist and γ-aminobutyric acid agonist)
and oral naltrexone (an opioid antagonist) were about equally
effective in preventing resumption of any drinking.

Naltrexone was also effective in reducing heavy drinking, but
acamprosate was not.
Disulfiram (an acetaldehyde dehydrogenase inhibitor) did not reduce
alcohol consumption..

Two off-label medications — nalmefene (an opioid antagonist) and
topiramate (an anticonvulsant) — were associated with improvements in
heavy drinking. There was insufficient evidence for other off-label
drugs, including SSRIs, tricyclic antidepressants, atypical
antipsychotics, and gabapentin.

JAMA article

FDA Approves New Omega-3 Supplement

The FDA has approved a new omega-3 supplement (brand name, Epanova) to 
treat adults with severe hypertriglyceridemia, defined as triglyceride 
levels 500 mg/dL or higher.

In its announcement, the manufacturer said that Epanova is the first 
omega-3 formulation approved by the FDA in free fatty acid form. It 
will be available in 1-g capsules and has been approved for 2-g and 4-
g dosages, which can be taken with or without food.

There are currently two other prescription formulations of omega-3 
supplements on the market: Lovaza and Vascepa. All three are approved 
only for the treatment of severe hypertriglyceridemia, though studies 
of expanded indications are underway.

By Larry Husten

Triple Therapy For Ulcerative Colitis

Response rates continue to be promising for amoxicillin, tetracycline, 
and metronidazole.

Bacteria are widely suspected to be one of the inciting antigens in 
ulcerative colitis (UC). As such, antibiotics, probiotics, and fecal 
microbiota transplantation have all been established or proposed as 
treatments for UC.

In the current open-label, multicenter trial, researchers assessed the 
efficacy of a combination of amoxicillin (500 mg), tetracycline (500 
mg), and metronidazole (250 mg) 3 times daily for 2 weeks to induce 
and maintain remission in patients refractory to or dependent on 
steroids. The same researchers had previously designed this regimen to 
treat elevated levels of Fusobacterium varium observed in inflamed 
colonic mucosa of patients with ulcerative colitis and serum 
antibodies to F. varium. The regimen was effective for short-term 
control of UC in a randomized, double-blind, placebo-controlled study 
(NEJM JW Gastroenterol Aug 27 2010).

Kato K et al. Aliment Pharmacol Ther 2014 May

Syphilis on the Rise, Especially in Men Who Have Sex with Men

Syphilis rates have nearly doubled in the past decade, with the 
steepest rise among men who have sex with men (MSM), according to an 
analysis of national data in MMWR.

From 2005 to 2013, annual rates of primary and secondary syphilis 
increased from 2.9 to 5.3 cases per 100,000 population. Increases were 
greatest among men, who accounted for 91% of cases in 2013, and were 
seen in men of all ages, races/ethnicities, and geographic regions. 
The rise was especially pronounced among MSM, who accounted for about 
80% of cases in men. Among women, rates increased from 2005 to 2008 
and dropped thereafter.

Notably, syphilis was at record low levels in 2000.

Calling the syphilis increase in MSM “a major public health concern,” 
the researchers recommend promoting prevention measures, including 
safer sex practices, syphilis screening, and partner notification.

MMWR article

Vitamin D2 or D3 as a supplement?

Vitamin D3 seems like the better choice for supplementation.

Despite considerable research, the health benefits of vitamin D 
supplementation in the general population remain controversial. In 
this systematic review and meta-analysis, investigators determined 
whether blood vitamin D levels and vitamin D supplementation were 
associated with risk for death.

One analysis involved 73 observational studies (mean follow-up, 0.3–
29 years) that involved 850,000 participants (median age, 63; median 
baseline blood 25-hydroxyvitamin D [25(OH)D] level, 20.7 ng/mL). 
Overall, compared with participants whose blood 25(OH)D levels were in 
the top third, those whose levels were in the bottom third had 
significantly greater risks for cardiovascular (CV)-related death 
(adjusted relative risk, 1.4), cancer-related death (ARR, 1.1), and 
all-cause death (ARR, 1.4). For each 10 ng/mL lower increment of 25(OH)
D, risk for all-cause death increased by 16%.

Another analysis involved 22 randomized, placebo-controlled trials 
(31,000 older participants; mean follow-up, 0.4–6.8 years) with data 
on the effect of vitamin D supplementation on all-cause mortality; 8 
trials provided vitamin D2 (dose range, 208–4500 IU/day), and 14 
trials provided vitamin D3 (dose range, 10–6000 IU/day). Vitamin D3 
supplementation significantly lowered mortality risk (relative risk, 
0.9), but vitamin D2 supplementation did not.

Comment

In this analysis, the observational data showed an inverse association 
between blood 25-hydroxyvitamin D levels and death, but reverse 
causality is possible (i.e., ill people having low vitamin D levels 
rather than low vitamin D levels causing illness). In randomized 
trials, vitamin D3 supplementation modestly lowered all-cause 
mortality risk; however, the optimal dose and duration of vitamin D3 
supplementation are unknown. Thus, widespread vitamin D 
supplementation should not be recommended.

Chowdhury R et al., BMJ 2014 
Apr 1; 348:g1903